Akso Health (US:AHG)2024-07-30 20:05Company Transition and Business Focus - The company transitioned from a P2P marketplace to a social e-commerce platform, changing its name from Hexindai Inc. to Akso Health Group in December 2021[223][238]. - The company disposed of its P2P business on December 30, 2020, and has since focused on healthcare services and products, including COVID-19 Rapid Antigen tests[242]. - In May 2023, the company completed the disposition of its social e-commerce business for cash consideration of $215,000[239]. - The company is no longer engaged in microlending or P2P businesses and is focusing on healthcare sector opportunities[242]. Subsidiaries and Acquisitions - The company established Qingdao Akso in January 2022 to sell medical devices, starting sales in April 2022, including defibrillators and anesthesia laryngoscopes[242]. - On March 5, 2024, the company acquired 50% equity interests in Tianjin Wangyi Cloud Co., Ltd., which provides online hospital services[240]. - The company has established multiple subsidiaries, including Akso Medical Cloud Limited and Akso Medi-care Limited, to expand its healthcare services[232][239]. - The company plans to acquire online hospitals in China to provide online medical consultations and chronic disease management, enhancing patient access to healthcare[243]. - The company aims to acquire multiple independent pharmacies across China to create a chain, leveraging offline resources and IT solutions to improve competitiveness[244]. - The company acquired 50% equity interest in Tianjin Wangyi Cloud Co., Ltd., which provides online hospital services, with the transaction closing on April 15, 2024[245]. Financial Performance - Revenue from medical equipment sales for the fiscal year ended March 31, 2024, was $2.4 million, representing 100% of the company's total revenue[253]. - The company reported net losses of US$9.5 million for the fiscal year ended March 31, 2024, compared to net losses of US$1.2 million and US$16.8 million for the fiscal years ended March 31, 2023 and 2022, respectively[376]. - Net revenues for the fiscal year ended March 31, 2024, were US$2.4 million, a decrease of 81.7% from US$13.2 million in the fiscal year ended March 31, 2023, primarily due to the cessation of Covid-19 test kit sales[376][397]. - The company recognized a gross profit of US$122,132 for the fiscal year ended March 31, 2024, down from US$1.27 million in 2023[393]. - Operating expenses for the fiscal year ended March 31, 2024, totaled US$8.76 million, a significant increase from US$15.54 million in 2023, driven by general and administrative expenses[386][393]. Regulatory Compliance and Legal Matters - The company has received all necessary licenses to engage in the resale of medical devices in China, including a Class II Medical Device Selling Record Certificate and a Class III Medical Device Operation License[252]. - The company must ensure compliance with advertising regulations for medical devices, which require advertisements to be true and legitimate[303]. - The company is subject to stringent regulations under the PRC Consumer Rights and Interests Protection Law, which mandates that consumers can return goods purchased online within seven days without stating a reason[293]. - The company must comply with foreign exchange regulations when converting RMB to foreign currency for capital account items, requiring approval from government authorities[310]. Management Team - Ms. Yilin (Linda) Wang has been the CEO since October 2021, previously serving as Co-CEO for one month[421]. - Ms. Rui (Kerrie) Zhang has been the CFO since August 2019, with prior experience in financial reporting and strategy development[422]. - Ms. Wang has extensive experience in corporate management and medical technology-related businesses[421]. - Ms. Zhang has a background in corporate governance and has held various roles in finance and investor relations[422].